Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

被引：55

作者：

Hussain, Nadiya ^{[1
]}

Naeem, Muntaha ^{[1
]}

Pinato, David J. ^{[1
]}

机构：

[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2021年 / 17卷 / 01期

基金：

英国惠康基金;

关键词：

antibiotics; corticosteroids; proton pump inhibitors; opioids; metformin; cancer immunotherapy; immune checkpoint inhibitors; PROTON PUMP INHIBITORS; GUT MICROBIOTA; EFFICACY; RISK;

D O I：

10.1080/21645515.2020.1769398

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The majority of cancer patients assume concomitant medications for the treatment of cancer-related symptoms or co-morbidities. As immune checkpoint inhibitors expand in the treatment of a widening range of malignancies, drug-drug interactions have become an area of increasing interest due to the potential for some concomitant medications to exert immune-modulatory effects and influence outcomes from immunotherapy. Here, we review the evidence supporting this association across selected drug classes including antibiotics, proton pump inhibitors, metformin, and opioids.

引用

页码：55 / 61

页数：7

共 63 条

[1] Could the menagerie of the gut microbiome really cure cancer? Hope or hype [J].

Abid, Muhammad Bilal .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[2] Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease [J].

Abu-Sbeih, Hamzah ;

Faleck, David M. ;

Ricciuti, Biagio ;

Mendelsohn, Robin B. ;

Naqash, Abdul R. ;

Cohen, Justine V. ;

Sellers, Maclean C. ;

Balaji, Aanika ;

Ben-Betzalel, Guy ;

Hajir, Ibraheim ;

Zhang, Jiajia ;

Awad, Mark M. ;

Leonardi, Giulia C. ;

Johnson, Douglas B. ;

Pinato, David J. ;

Owen, Dwight H. ;

Weiss, Sarah A. ;

Lamberti, Giuseppe ;

Lythgoe, Mark P. ;

Manuzzi, Lisa ;

Arnold, Christina ;

Qiao, Wei ;

Naidoo, Jarushka ;

Markel, Gal ;

Powell, Nick ;

Yeung, Sai-Ching J. ;

Sharon, Elad ;

Dougan, Michael ;

Wang, Yinghong .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) :576-+

[3]

Acharya C, 2017, ALIMENT PHARM THER, V45, P319, DOI [10.1111/apt.13858, 10.1111/apt.14585]

[4] Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors [J].

Afzal, Muhammad Z. ;

Dragnev, Konstantin ;

Sarwar, Tayyaba ;

Shirai, Keisuke .

LUNG CANCER MANAGEMENT, 2019, 8 (02)

[5] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma [J].

Afzal, Muhammad Zubair ;

Mercado, Rima R. ;

Shirai, Keisuke .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[6] Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors [J].

Ahmed, Jibran ;

Kumar, Arun ;

Parikh, Kaushal ;

Anwar, Asad ;

Knoll, Bettina M. ;

Puccio, Carmelo ;

Chun, Hoo ;

Fanucchi, Michael ;

Lim, Seah H. .

ONCOIMMUNOLOGY, 2018, 7 (11)

[7] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].

Arbour, Kathryn C. ;

Mezquita, Laura ;

Long, Niamh ;

Rizvi, Hira ;

Auclin, Edouard ;

Ni, Andy ;

Martinez-Bernal, Gala ;

Ferrara, Roberto ;

Lai, W. Victoria ;

Hendriks, Lizza E. L. ;

Sabari, Joshua K. ;

Caramella, Caroline ;

Plodkowski, Andrew J. ;

Halpenny, Darragh ;

Chaft, Jamie E. ;

Planchard, David ;

Riely, Gregory J. ;

Besse, Benjamin ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+

[8] Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation [J].

Banerjee, S. ;

Sindberg, G. ;

Wang, F. ;

Meng, J. ;

Sharma, U. ;

Zhang, L. ;

Dauer, P. ;

Chen, C. ;

Dalluge, J. ;

Johnson, T. ;

Roy, S. .

MUCOSAL IMMUNOLOGY, 2016, 9 (06) :1418-1428

[9] Drug interactions in oncology [J].

Beijnen, JH ;

Schellens, JHM .

LANCET ONCOLOGY, 2004, 5 (08) :489-496

[10] Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis [J].

Biswas, Sangita ;

Benedict, Stephen H. ;

Lynch, Sharon G. ;

LeVine, Steven M. .

BMC MEDICINE, 2012, 10

← 1 2 3 4 5 6 7 →